RTX-321 Monotherapy in Patients With HPV 16+ Tumors
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321
for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or
metastatic, unresectable, HPV 16+ cancers.